Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2019 15:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session

PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects Results support continued development of PB2452 as ticagrelor reversal agent MALVERN, Penn. and SAN DIEGO, March ...
March 06, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference

MALVERN, Pa. and SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
March 04, 2019 08:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Appoints Richard A. van den Broek to Board of Directors

MALVERN, Pa., and SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
March 04, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session

MALVERN, Pa., and SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
December 17, 2018 16:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Appoints Edmund P. Harrigan to Board of Directors

MALVERN, Pa. and SAN DIEGO, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
November 29, 2018 16:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Reports Third Quarter 2018 Financial and Business Results

Closed initial public offering that raised $43.0 million in net proceeds Demonstrated proof of concept for PB2452, supporting continued development for the reversal of antiplatelet activity of...
November 27, 2018 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension

MALVERN, Pa. and SAN DIEGO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
November 21, 2018 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018

MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
November 07, 2018 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio to Present at Stifel 2018 Healthcare Conference

MALVERN, Pa. and SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
October 17, 2018 19:24 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Pricing of Initial Public Offering

MALVERN, Pa. and SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization...